Oct. 1, 2007 , 2007 - Discovery Laboratories, Inc. (NasdaqGM:DSCO) today announces that its new Surfaxin(r) (lucinactant) process validation batches have demonstrated acceptable stability at six months under Discovery Labs' comprehensive stability testing protocol. This six-month stability data will be included, along with other data and information, in a formal response to the U.S. Food and Drug Administrations' (FDA) April 2006 Approvable Letter for Surfaxin for the prevention of Respiratory Distress Syndrome (RDS) in premature infants... Discovery Laboratories' Press Release [PDF] -
Oct 2, 2007
Discovery Laboratories, Surfaxin Process Validation Batches
Oct. 1, 2007 , 2007 - Discovery Laboratories, Inc. (NasdaqGM:DSCO) today announces that its new Surfaxin(r) (lucinactant) process validation batches have demonstrated acceptable stability at six months under Discovery Labs' comprehensive stability testing protocol. This six-month stability data will be included, along with other data and information, in a formal response to the U.S. Food and Drug Administrations' (FDA) April 2006 Approvable Letter for Surfaxin for the prevention of Respiratory Distress Syndrome (RDS) in premature infants... Discovery Laboratories' Press Release [PDF] -
